Business
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast
ALAMEDA, Calif.--(BUSINESS WIRE)-- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing
About this update from Vivani Medical, Inc.
[{"type":"text","content":" ALAMEDA, Calif.--(BUSINESS WIRE)--\nVivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the Innovation in Obesity Therapeutics Summit West Coast, taking place in San Diego, California, from December 10-12, 2024.\n\n\nEvent details are as follows:\n\n\nPanel Discussion: The Obesity Race on the Manufacturing Floor – Exploring Supply Challenges with Innovations in Discovery\nPanel Date: Wednesday, December 11, 2024\nPanel Time: 2:40 pm, Pacific Time\n\n\nDr. Mendelsohn will be joined by Feng Liu, Executive Director at Regor Therapeutics, and David Bearss, co-founder and Chairman at Biolexis Therapeutics, in a panel discussion of supply chain challenges for GLP-1 drugs and the innovative solutions that are being explored to address these issues.\n\n\nPresentation: Advancing Chronic Disease Management with Ultra Long-Acting Miniature Subdermal Implants of GLP-1\nPresentation Date: Wednesday, December 11, 2024\nPresentation Time: 4:20pm, Pacific Time\n\n\nIn this session, Dr. Mendelsohn will provide an overview of Vivani’s emerging portfolio of miniature, drug implant candidates designed to revolutionize the treatment of chronic diseases by leveraging the company’s proprietary NanoPortal™ implant technology. The Company’s lead program, NPM-119, is a six-month GLP-1 (exenatide) implant in development for chronic weight management. Clinical data from LIBERATE-1, the first-in-human, study in obese and overweight individuals, is expected in 2025. These ultra long-acting implants are designed for once or twice-yearly dosing and directly address main [major] challenges to optimal treatment, including poor medication adherence and potentially poor patient tolerability.\n\n\nMore information about Innovation in Obesity Therapeutics Summit West Coast can be found at https://innovation-obesity-summit.com/.\n\n\nAbout Vivani Medical, Inc.\n\n\nLeveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Vivani’s lead program, ...